Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | PPM1B | O75688 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1765120 | 1.00 | KMT2A (0.38) | KMT2ACHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL24750125 | 0.81 | KMT2A (0.41) | KMT2ACHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL2028983 | 0.79 | HRH3 (0.32) | CHRM2CHRM3 | |
| SCHEMBL1613612 | 0.74 | CYP2D6 (0.40) | KMT2A | |
| SCHEMBL6984736 | 0.72 | GLI1 (0.38) | — | |
| SCHEMBL19919907 | 0.72 | — | — | |
| SCHEMBL22362536 | 0.69 | CHRNB2 (0.40) | KMT2ACHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL6285170 | 0.69 | CHRM2 (0.42) | KMT2ACHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL6285175 | 0.69 | CHRM2 (0.42) | KMT2ACHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL6513544 | 0.69 | CHRM2 (0.42) | KMT2ACHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023209090-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AND THEIR APPLICATION IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2023-11-02 | — | — | WO | disclosed |
| CN-111065630-B | Internal sulfonamide compound crystal | 正大天晴药业集团股份有限公司 | 2022-12-30 | — | — | CN | disclosed |
| CN-113666922-A | Internal sulfonamide compounds and methods of use thereof | 正大天晴药业集团股份有限公司 | 2021-11-19 | — | — | CN | disclosed |
| CN-109071471-B | Internal sulfonamide compounds and methods of use thereof | 正大天晴药业集团股份有限公司 | 2021-05-07 | — | — | CN | disclosed |
| CN-111065630-A | Internal sulfonamide compound crystal | 正大天晴药业集团股份有限公司 | 2020-04-24 | — | — | CN | disclosed |
| EP-2565182-B1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORP (JP) | 2017-10-11 | — | — | EP | disclosed |
| CN-102753538-B | Sultam derivatives | HOFFMANN LA ROCHE | 2015-04-08 | — | — | CN | disclosed |
| EP-2504324-B1 | SULTAM DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2015-02-25 | — | — | EP | disclosed |
| US-8816079-B2 | Amide derivative and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-08-26 | — | — | US | disclosed |
| US-20130040930-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-02-14 | — | — | US | disclosed |
| US-8314250-B2 | Sultam derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-8314250-B2 | Sultam derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-11-20 | — | — | US | disclosed |
| CN-102753538-A | Sultam derivatives | HOFFMANN LA ROCHE | 2012-10-24 | — | — | CN | disclosed |
| US-20110136792-A1 | NOVEL CARBOXYLIC ACID ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-06-09 | — | — | US | disclosed |
| US-20110136792-A1 | NOVEL CARBOXYLIC ACID ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-06-09 | — | — | US | disclosed |
| US-20110136792-A1 | NOVEL CARBOXYLIC ACID ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | BOLIN DAVID ROBERT | 2011-06-09 | — | — | US | disclosed |
| WO-2011064141-A1 | SULTAM DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-03 | — | — | WO | disclosed |
| US-20110124686-A1 | SULTAM DERIVATIVES | ANDERSON KEVIN W | 2011-05-26 | — | — | US | disclosed |
| US-20110124686-A1 | SULTAM DERIVATIVES | ANDERSON KEVIN W | 2011-05-26 | — | — | US | disclosed |
| EP-0342456-A2 | Sultamsulfonamide derivatives and herbicides | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1989-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136792-A1 | NOVEL CARBOXYLIC ACID ANALOGS AS GLYCOGEN SYNTHASE ACTIVATORS | GYS2, GYS1, PYGL | KMT2A 3673/4885CHRNB2 1667/4885CHRNA4 2210/4885 |
| US-20130040930-A1 | NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE | MMP9, MMP10, MMP2 | KMT2A 685/4885CHRNB2 4831/4885CHRNA4 4833/4885 |
| US-20110124686-A1 | SULTAM DERIVATIVES | SULT1A1, SULT2A1, SULT1E1 | KMT2A 639/4885CHRNB2 4742/4885CHRNA4 4737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.